On November 13, 2024, David Mott, Director at Ardelyx Inc (ARDX, Financial), purchased 215,868 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now owns a total of 1,425,465 shares of Ardelyx Inc.
Ardelyx Inc focuses on developing innovative, first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases. The insider's recent purchase marks a significant addition to their holdings in the company.
Over the past year, the insider has increased their stake in the company by purchasing 215,868 shares and has not sold any shares. This trend in insider activity can be visualized in the following insider trend image:
The transaction history for Ardelyx Inc shows a total of 1 insider buy and 71 insider sells over the past year. This pattern of insider transactions provides a broader context to the insider's recent buying activity.
On the valuation front, Ardelyx Inc was trading at $4.62 per share on the day of the insider's purchase. The company has a market cap of approximately $1.12 billion. According to the GF Value, which is an intrinsic value estimate from GuruFocus, the stock has a GF Value of $13.33. This results in a price-to-GF-Value ratio of 0.35, suggesting that the stock is a Possible Value Trap, Think Twice.
The GF Value is determined by historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on past returns and growth, and future business performance estimates from Morningstar analysts.
The following GF Value image provides further insight into the valuation:
This recent insider purchase could be of interest to current and potential investors, providing a signal to reevaluate the company's stock under the current market conditions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
